Henri Jasper (via Buck Institute for Research on Aging)

An Al­tos Labs ri­val? Genen­tech throws its hat in­to buzzy 'cel­lu­lar re­ju­ve­na­tion' field

Just a few short months af­ter Al­tos Labs made its de­but flush with $3 bil­lion in cash, a fa­mous CEO and a star-stud­ded sci­en­tif­ic team, the cel­lu­lar re­ju­ve­na­tion biotech may now be see­ing the first inklings of a com­peti­tor: Genen­tech.

The large biotech and Roche sub­sidiary pub­lished in Na­ture Ag­ing last week on cel­lu­lar re­ju­ve­na­tion. Al­though it’s still ear­ly and the ap­proach faces huge hur­dles be­fore reach­ing hu­mans, this is one of the first times that a large, well-known biotech has shown in­ter­est in the field that Al­tos is try­ing to pi­o­neer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.